טוען...
Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59
Immunotherapy using MoAbs is inefficient due to limited activation of human effectors by mouse antibodies and multiple protective mechanisms available to host cells against autologous complement. We have used chemically engineered antibody constructs and human complement in vitro to specifically tar...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Blackwell Science Inc
1997
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1904584/ https://ncbi.nlm.nih.gov/pubmed/9030877 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2249.1997.265-ce1156.x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|